search
Back to results

Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT (ADERE (Ped))

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Telephone follow-up
No telephone follow-up
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Treatment compliance, Pediatric, Asthma

Eligibility Criteria

6 Years - 14 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Signature of a informed consent form
  • Age between 6 and 14 years old
  • Diagnosis of persistent moderate or severe asthma, according to III Brazilian Consensus on Asthma Management.
  • Home telephone available

Exclusion criteria:

  • Co-morbidities that may interfere with the study evaluation or that require continuous drugs, e.g., cardiopathy, gastro-esophageal reflux or diabetes.
  • Continuous systemic corticosteroid use for more than seven days
  • The patient has been treated or is being treated with allergen-specific immunetherapy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    telephone follow-up

    No telephone follow-up

    Arm Description

    Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.

    Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.

    Outcomes

    Primary Outcome Measures

    The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.

    Secondary Outcome Measures

    Disease control, evaluated by information in the questionnaires.
    Regular medical attention sought, evaluated by information in the questionnaires
    Additional resources in the event of attacks
    Improvement in the quality of life.
    Increase in the weekly number of nocturnal awakening or the number of awakenings per night
    Increase in the use of rescue drug

    Full Information

    First Posted
    March 4, 2010
    Last Updated
    June 26, 2017
    Sponsor
    GlaxoSmithKline
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01476059
    Brief Title
    Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
    Acronym
    ADERE (Ped)
    Official Title
    Prospective, Parallel-group, Randomized Study to Evaluate the Compliance to the Treatment of Children Aged Between 6 and 14 Years Old With Persistent Moderate or Severe Asthma, Receiving the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose Twice a Day. ADERE PROJECT
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2004 (undefined)
    Primary Completion Date
    December 2004 (Actual)
    Study Completion Date
    December 2004 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    GlaxoSmithKline

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose and Salmeterol 50 mcg/dose twice a day. ADERE PROJECT (Pediatric)
    Detailed Description
    Objectives General: To evaluate the compliance degree to the treatment of asthmatic children, according to the attention received. Specific: To study asthmatic compliance to the treatment proposed, aiming at an association with other factors, such as: parents' instruction, hospitalizations, personal and family history of atopy, co-morbidities, severity of the disease and use of other drugs. To study asthmatic compliance to the treatment proposed, associating it with the impact in quality of life, though the application of a specific questionnaire. Outcomes The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered. The following will be considered as secondary outcomes: Disease control, evaluated by information in the questionnaires. Regular medical attention sought, evaluated by information in the questionnaires. Additional resources in the event of attacks, increase in the weekly number of nocturnal awakening or the number of awakenings per night, increase in the use of rescue drug. Improvement in the quality of life. Casuistic and Method Study groups Asthmatic children aged 6 to 14 years old from both sexes, with persistent mild, moderate or sever asthma classified according to the criteria from the III - Brazilian Consensus on Asthma Management. Group I - Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals. Group II - Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians. Study Design This is a prospective, controlled, randomized, parallel-group study, with the inclusion of 472 children presenting persistent moderate or severe asthma. Our researchers developed the study, and it will be performed only in Brazil, solely by our Clinical Research Center. The drug to be used is in accordance with the main International Consensus on Asthma Treatment and with the III - Brazilian Consensus on Asthma Management, being marketed for some years in Brazil. During patient recruitment and screening, their parents or guardians will fill out the free informed consent form. At this time, they will also be given the drug (Seretide Diskus® 50/250) with doses enough for a 90-day treatment, twice a day, in addition to instructions on the use of the device to apply the drug and guidance from his/her physician on how to act in the event of an attack. After study inclusion, the study will receive a number which will randomly include him/her in group 1 or 2 of this study. Patients included in group 1 will receive two types of telephone calls: A. Investigation telephone call - TI: that will be made by a trained health professional from the Centro de Pesquisa Clínica e Medicina Avançada, aiming at: presentation, data collection on asthma, including demographics and relevant clinical history (details on asthma, previous exacerbations, drugs used, etc), submission of a standardized checking questionnaire (questionnaire 1 - attachment 1) and quality of life questionnaire (questionnaire 2 - attachment 2). By 90 days, the patient's guardian will receive the last investigation telephone call (TI -2) in order to apply the quality of life questionnaire and standardized evaluation questionnaire (questionnaire 1 - attachment 1) B. Compliance telephone call - TA: A specifically trained professional will make follow-up telephone calls at every fifteen days, according to a pre-established guide (Attachment 4), requesting the patient to answer the questions pursuant to the follow-up questionnaire (attachment 3) and clarifying probable doubts on the drug application, however, without interfering with the treatment prescribed by the physician. Patients included in group 2 will receive only the Investigation Telephone call (TI) All telephone contacts will be made for the same person: mother, father or guardian. By the end of week 12, the persons responsible for the patients will return, by mail, the drug to Centro de Pesquisa Clínica e Medicina Avançada.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma
    Keywords
    Treatment compliance, Pediatric, Asthma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    472 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    telephone follow-up
    Arm Type
    Other
    Arm Description
    Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
    Arm Title
    No telephone follow-up
    Arm Type
    Other
    Arm Description
    Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
    Intervention Type
    Other
    Intervention Name(s)
    Telephone follow-up
    Intervention Description
    Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
    Intervention Type
    Other
    Intervention Name(s)
    No telephone follow-up
    Intervention Description
    Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
    Primary Outcome Measure Information:
    Title
    The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.
    Time Frame
    After 90 days of treatment
    Secondary Outcome Measure Information:
    Title
    Disease control, evaluated by information in the questionnaires.
    Time Frame
    After 90 days of treatment
    Title
    Regular medical attention sought, evaluated by information in the questionnaires
    Time Frame
    After 90 days of treatment
    Title
    Additional resources in the event of attacks
    Time Frame
    After 90 days of treatment
    Title
    Improvement in the quality of life.
    Time Frame
    After 90 days of treatment
    Title
    Increase in the weekly number of nocturnal awakening or the number of awakenings per night
    Time Frame
    After 90 days of treatment
    Title
    Increase in the use of rescue drug
    Time Frame
    After 90 days of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Years
    Maximum Age & Unit of Time
    14 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion criteria: Signature of a informed consent form Age between 6 and 14 years old Diagnosis of persistent moderate or severe asthma, according to III Brazilian Consensus on Asthma Management. Home telephone available Exclusion criteria: Co-morbidities that may interfere with the study evaluation or that require continuous drugs, e.g., cardiopathy, gastro-esophageal reflux or diabetes. Continuous systemic corticosteroid use for more than seven days The patient has been treated or is being treated with allergen-specific immunetherapy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    GSK Clinical Trials
    Organizational Affiliation
    GlaxoSmithKline
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT

    We'll reach out to this number within 24 hrs